Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avacopan - ChemoCentryx/Vifor Fresenius Medical Care Renal Pharma

Next Previous
X
Search
Drug Profile

Avacopan - ChemoCentryx/Vifor Fresenius Medical Care Renal Pharma

Alternative Names: AMG-569; CCX 168; TAVNEOS; Tavneos; Vynpenta

Latest Information Update: 29 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ChemoCentryx
  • Developer Amgen; ChemoCentryx; Kissei Pharmaceutical; Medpace; Vifor Fresenius Medical Care Renal Pharma
  • Class Amides; Anti-inflammatories; Cyclopentanes; Fluorinated hydrocarbons; Piperidines; Skin disorder therapies; Small molecules; Urologics
  • Mechanism of Action Complement C5a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Granulomatosis with polyangiitis; Microscopic polyangiitis; Anti-neutrophil cytoplasmic antibody-associated vasculitis; Membranoproliferative glomerulonephritis; Haemolytic uraemic syndrome
  • New Molecular Entity Yes
  • Available For Licensing Yes - Anti-neutrophil cytoplasmic antibody-associated vasculitis

Highest Development Phases

  • Marketed Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Phase III Membranoproliferative glomerulonephritis
  • Phase II Haemolytic uraemic syndrome; Hidradenitis suppurativa; IgA nephropathy
  • No development reported Liver disorders

Most Recent Events

  • 05 Oct 2024 Amgen completes a phase I pharmacokinetics trial in healthy subjects and renal failure in USA (PO) (NCT06468826)
  • 06 Aug 2024 Phase-III clinical trials in Anti-neutrophil cytoplasmic antibody-associated vasculitis (In children, In adolescents) (PO, Liquid) in USA (NCT06321601)
  • 06 Aug 2024 Phase-III clinical trials in Anti-neutrophil cytoplasmic antibody-associated vasculitis (In children, In adolescents) (PO, Tablet) in USA (NCT06321601)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top